Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY: Solriamfetol in MDD with Excessive Daytime Sleepiness
NCT07484217Phase 3Recruiting
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Solriamfetol 150mg with Placebo (2 arms). Primary endpoint: Time from randomization to relapse of depressive symptoms up to 24 weeks. Started Feb 2026; status: recruiting.
02
Drugs
solriamfetol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07484217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484217.